Suven Life Sciences Ltd

- No explicit mention of plans for new fundraising through debt or equity in the provided pages. - Existing debt of Rs.150 crore is discussed, with debt staying with the Suven Pharma entity post-demerger. - CAPEX plans of around Rs.130-140 crore for the current year and about Rs.100 crore the next year are mentioned, but no indication that new fundraising is needed for these. - Rising Pharma's consolidation is pending due to US bankruptcy proceedings; no new investment infusion is currently necessary as per Venkat Jasti. - Cash balance of Rs.150 crore including mutual funds is available; cash generation is expected, to partly fund CAPEX and operations. - No direct mention of planned equity raising or further debt borrowings; emphasis is on utilizing existing funds and proceeds. In summary, based on the transcript, there is no current or imminent new fundraising through debt or equity planned.

- Total CAPEX planned around Rs. 130-140 crore this year, approximately Rs. 100 crore in the current financial year and Rs. 50 crore in the next year. (Page 12, Page 8) - Out of Rs. 320 crore overall CAPEX, Rs. 160 crore is to be spent soon; Rs. 100 crore already spent on Pashamylaram facility, to be capitalized by Q3; facilities in Vizag and formulations expected to be ready by end of next year's Q3. (Page 10) - Additional maintenance CAPEX around Rs. 30-40 crore separate from new CAPEX. (Page 11) - Rs. 150 crore pending CAPEX is planned, with investment ongoing in occupational exposure level facility in Pashamylaram, to be commercialized soon. (Page 6) - CAPEX expected to support capacity expansion for CRAMS and generic business growth, but only six months visibility currently available. (Page 6) - No major CAPEX anticipated for Rising Pharma as it is a development and distribution company without major asset base. (Page 14)

- Commercial CRAMS revenue is expected to be around Rs.180-190 crore for the current year, with a possibility of reaching up to Rs.190 crore, though Q2 numbers may not repeat consistently. - Specialty Chemicals revenue is anticipated to grow modestly from Rs.210 crore to approximately Rs.220-230 crore in the full year, with a 5-10% growth range. - Regular CRAMS may grow at about 10-20% over the next six months and FY’21, subject to customer success and normal business conditions. - Two more specialty chemical molecules are in early development, expected to become commercial around FY’21 or FY’22. - Overall CAPEX is Rs.130-140 crore in the current year and Rs.100-120 crore next year, supporting growth. - Some fluctuation in quarterly revenue is expected due to lumpiness in order timing and product launches. - Future growth is cautiously optimistic but dependent on client approvals and clinical trial success of key molecules.

- Earnings growth is reflected in a 62% increase in half-year income, 115% in EBITDA, and 128% in net profit (Page 1). - Specialty Chemicals revenue might see a 5-10% growth from Rs. 210 crore to about Rs. 220-230 crore annually (Pages 8 and 14). - Commercial CRAMS guidance remains Rs. 180-190 crore for FY’20, with possibilities up to Rs. 190 crore, but quarterly steady-state numbers are uncertain due to order lumpiness (Pages 2, 8, 14). - Core CRAMS may grow by 10-20% over the next six months barring customer attrition (Page 2). - R&D expenses expected around $10 million annually; some ongoing molecule developments may impact future growth but with inherent uncertainties (Page 11). - Specialty chemicals revenue expected stable till FY’22, pending new molecule launches (Page 10). - Visibility of growth beyond six months limited; projections are based on short-term visibility and can vary (Pages 2, 10, 14).

- The order book or pending orders are discussed in terms of molecules in different phases (P1, P2, P3, commercial). - There is a net addition of only one molecule during the year due to attrition and addition, with about 40% portfolio churn (Page 10). - The company cannot give steady-state quarterly orderbook or steady revenue from commercial molecules due to variable sales timelines which can be once a year or once in 15-18 months (Page 14). - Commercial CRAMS revenue was Rs. 107 crore this quarter, with total CRAMS at Rs. 206 crore (Page 2). - Guidance on commercial CRAMS revenue for full year FY'20 is Rs. 180-190 crore, potentially going up to Rs. 190 crore (Page 2). - CAPEX related to expanding capacity is ongoing to meet order demand, with facilities expected to come online end of next year (Page 7, Page 6).